271 related articles for article (PubMed ID: 26746169)
1. Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.
Jairath V; Zou G; Parker CE; Macdonald JK; Mosli MH; Khanna R; Shackelton LM; Vandervoort MK; AlAmeel T; Al Beshir M; AlMadi M; Al-Taweel T; Atkinson NS; Biswas S; Chapman TP; Dulai PS; Glaire MA; Hoekman D; Koutsoumpas A; Minas E; Samaan MA; Travis S; D'Haens G; Levesque BG; Sandborn WJ; Feagan BG
J Crohns Colitis; 2016 May; 10(5):607-18. PubMed ID: 26746169
[TBL] [Abstract][Full Text] [Related]
2. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.
Jairath V; Zou GY; Parker CE; MacDonald JK; AlAmeel T; Al Beshir M; Almadi MA; Al-Taweel T; Atkinson NS; Biswas S; Chapman T; Dulai PS; Glaire MA; Hoekman DR; Koutsoumpas A; Minas E; Mosli MH; Samaan M; Khanna R; Travis S; D'Haens G; Sandborn WJ; Feagan BG
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011572. PubMed ID: 28886205
[TBL] [Abstract][Full Text] [Related]
3. Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.
Sedano R; Hogan M; Nguyen TM; Chang J; Zou GY; Macdonald JK; Vande Casteele N; Hanzel J; Crowley E; Battat R; Dulai PS; Singh S; D'Haens G; Sandborn W; Feagan BG; Ma C; Jairath V
J Crohns Colitis; 2022 Feb; 16(2):224-243. PubMed ID: 34309658
[TBL] [Abstract][Full Text] [Related]
4. Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis.
Ma C; Guizzetti L; Panaccione R; Fedorak RN; Pai RK; Parker CE; Nguyen TM; Khanna R; Vande Casteele N; D'Haens G; Sandborn WJ; Feagan BG; Jairath V
Aliment Pharmacol Ther; 2018 Jun; 47(12):1578-1596. PubMed ID: 29696670
[TBL] [Abstract][Full Text] [Related]
5. Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease.
Jairath V; Zou G; Parker CE; MacDonald JK; Mosli MH; AlAmeel T; Al Beshir M; AlMadi M; Al-Taweel T; Atkinson NS; Biswas S; Chapman TP; Dulai PS; Glaire MA; Hoekman D; Kherad O; Koutsoumpas A; Minas E; Restellini S; Samaan MA; Khanna R; Levesque BG; D'Haens G; Sandborn WJ; Feagan BG
Aliment Pharmacol Ther; 2017 Apr; 45(8):1021-1042. PubMed ID: 28164348
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis.
Su C; Lewis JD; Goldberg B; Brensinger C; Lichtenstein GR
Gastroenterology; 2007 Feb; 132(2):516-26. PubMed ID: 17258720
[TBL] [Abstract][Full Text] [Related]
7. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
Cholapranee A; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
Aliment Pharmacol Ther; 2017 May; 45(10):1291-1302. PubMed ID: 28326566
[TBL] [Abstract][Full Text] [Related]
8. Vedolizumab for induction and maintenance of remission in ulcerative colitis.
Bickston SJ; Behm BW; Tsoulis DJ; Cheng J; MacDonald JK; Khanna R; Feagan BG
Cochrane Database Syst Rev; 2014 Aug; (8):CD007571. PubMed ID: 25105240
[TBL] [Abstract][Full Text] [Related]
9. Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies.
Ma C; Guizzetti L; Cipriano LE; Parker CE; Nguyen TM; Gregor JC; Chande N; Feagan BG; Jairath V
Aliment Pharmacol Ther; 2019 Feb; 49(4):364-374. PubMed ID: 30569460
[TBL] [Abstract][Full Text] [Related]
10. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
11. Histological Remission Placebo Rates in Ulcerative Colitis Trials: A Systematic Review and Meta-analysis.
Youssef M; Dong K; Lee SJ; Narula N
Inflamm Bowel Dis; 2024 Jan; 30(1):125-131. PubMed ID: 36753516
[TBL] [Abstract][Full Text] [Related]
12. Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Battat R; Duijvestein M; Guizzetti L; Choudhary D; Boland BS; Dulai PS; Parker CE; Nguyen TM; Singh S; Vande Casteele N; Pai RK; Feagan BG; Sandborn WJ; Jairath V
Am J Gastroenterol; 2019 May; 114(5):733-745. PubMed ID: 30694863
[TBL] [Abstract][Full Text] [Related]
13. Type I interferons for induction of remission in ulcerative colitis.
Seow CH; Benchimol EI; Griffiths AM; Steinhart AH
Cochrane Database Syst Rev; 2008 Jul; (3):CD006790. PubMed ID: 18646167
[TBL] [Abstract][Full Text] [Related]
14. Placebo Rates in Randomized Controlled Trials of Pouchitis Therapy.
Athayde J; Davies SC; Parker CE; Guizzetti L; Ma C; Khanna R; Feagan BG; Jairath V
Dig Dis Sci; 2018 Oct; 63(10):2519-2528. PubMed ID: 29995184
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis.
Chen X; Hou J; Yuan Y; Huang C; Liu T; Mo C; Li H; Chen B; Xu Q; Hou Z; He W; Liu F
BioDrugs; 2016 Jun; 30(3):207-17. PubMed ID: 27120055
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials.
Zhang ZM; Li W; Jiang XL
Gut Liver; 2016 Mar; 10(2):262-74. PubMed ID: 26780088
[TBL] [Abstract][Full Text] [Related]
17. Clinical, Endoscopic, and Safety Placebo Rates in Induction and Maintenance Trials of Crohn's Disease: Meta-Analysis of Randomised Controlled Trials.
Almradi A; Sedano R; Hogan M; Zou GY; MacDonald JK; Parker CE; Hanzel J; Crowley E; Singh S; D'Haens G; Sandborn WJ; Feagan BG; Ma C; Jairath V
J Crohns Colitis; 2022 Jun; 16(5):717-736. PubMed ID: 34758084
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; van Assche G; Reinisch W; Colombel JF; D'Haens G; Wolf DC; Kron M; Tighe MB; Lazar A; Thakkar RB
Gastroenterology; 2012 Feb; 142(2):257-65.e1-3. PubMed ID: 22062358
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
[TBL] [Abstract][Full Text] [Related]
20. Factors predicting clinical and endoscopic remission with placebo therapy in East Asian patients with ulcerative colitis: a systematic review and meta-analysis.
Zeng J; Wang Z; Yang XJ
Eur J Clin Pharmacol; 2022 Jul; 78(7):1069-1077. PubMed ID: 35347342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
